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Abstract
Background: Recently, supplementation of L-carnitine to obese rats was found to improve the carnitine status and to
counteract an obesity-induced muscle fiber transition from type I to type II. However, it has not been resolved if the
change of muscle fiber distribution induced in obese rats and the restoration of the “normal” muscle fiber distribution,
which is found in lean rats, in obese rats by supplemental L-carnitine is causally linked with the carnitine status. In the
present study we hypothesized that fiber type distribution in skeletal muscle is dependent on carnitine status.
Methods: To test this, an experiment with 48 piglets which were randomly allocated to four groups (n = 12) was
performed. All piglets were given orally either 60 mg sodium bicarbonate/kg body weight (group CON), 20 mg
L-carnitine and 60 mg sodium bicarbonate/kg body weight (group CARN), 30 mg pivalate (dissolved in sodium
bicarbonate)/kg body weight (group PIV) or 20 mg L-carnitine and 30 mg pivalate/kg body weight (group CARN + PIV)
each day for a period of 4 weeks.
Results: Concentrations of total carnitine in plasma, liver and longissimus dorsi and biceps femoris muscles were 2.0–2.
7 fold higher in group CARN than in group CON, whereas these concentrations were 1.9–2.5-fold lower in group PIV
than in group CON. The concentrations of total carnitine in these tissues did not statistically differ between group
CARN + PIV and group CON. Fiber type distribution of longissimus dorsi and biceps femoris muscles, mRNA and
protein levels of molecular regulators of fiber distribution in longissimus dorsi and biceps femoris muscles and mRNA
levels of genes reflecting the metabolic phenotype of longissimus dorsi and biceps femoris muscles did not differ
between groups.
Conclusion: Changes in the systemic carnitine status and the muscle carnitine concentration induced by either
supplementing L-carnitine or administering pivalate have no impact on the contractile and metabolic phenotype of
skeletal muscles in pigs.
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Background
Individual skeletal muscles in the body have distinct
contractile and metabolic functions depending on their
location in the body and the kind of muscular effort.
The anatomic basis for the distinct functions of individ-
ual skeletal muscles is their specific distribution pattern
of muscle fibers, from which two major types differing
in their myosin heavy chain (MHC) isoforms and their
enzymatic capacity [1] can be distinguished. It has long
been known that the oxidative type I fibers expressing
MHC I are mitochondria-rich, have a high oxidative
capacity utilizing mostly oxidative phosphorylation for
energy production, while the glycolytic type II fibers,
which are subdivided into IIA expressing MHC IIa, IIb
expressing MHC IIb and IIx expressing MHC IIx, have a
lower oxidative capacity due to fewer mitochondria
content than type I muscle fibers and thus depend on
glycolytic metabolism to generate ATP [2]. According to
recent evidence, the different energy substrate preferences
between the two major types of muscle fibers are not only
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explained by the different number of mitochondria but
also by mitochondrial specialization across fiber types with
regard to regulation of oxidative phosphorylation,
dynamics of reactive oxygen species, handling of Ca2+ and
regulation of cell death [3].
Noteworthy, the fiber distribution of a given muscles
shows high plasticity and can be induced to switch depend-
ing on various factors, like exercise, mechanical unloading
and obesity, thereby leading to a change of the muscle’s
metabolic phenotype [4–7]. With regard to obesity, it has
been shown that obese subjects have a lower percentage of
type I and a higher percentage of type II fibers and an im-
paired mitochondrial oxidative enzyme capacity in skeletal
muscle than lean counterparts [7, 8] indicating that type I
fibers are initiated to switch into type II fibers during obes-
ity development. Interestingly, we have found recently that
supplementation of L-carnitine to obese rats counteracts
the obesity-induced muscle fiber transition from type I to
type II through inducing genes encoding critical molecular
regulators of muscle fiber transition, like peroxisome
proliferator-activated receptor δ (PPARδ encoded by
PPARD), PPARγ coactivator-1α (PGC-1α encoded by
PPARGC1A) and PGC-1β (PPARGC1B) [9–12], and
thereby favours an oxidative metabolic phenotype of skel-
etal muscle [13]. L-Carnitine is a water soluble quaternary
amine which is essential for normal function of all tissues
and is derived from both dietary sources (meat and dairy
products) and endogenous biosynthesis [14]. The most
reported function of L-carnitine is its role in the import of
long-chain fatty acids from the cytosol into the mitochon-
drial matrix for subsequent β-oxidation [15]. However, L-
carnitine is generally important for proper functioning of
intermediary metabolism considering that deficiency of L-
carnitine is associated not only with impaired fatty acid
utilization but also with perturbations of glucose utilization
and insulin sensitivity [16].
We have also found in our recent study that obese rats
receiving no supplemental L-carnitine had significantly
lower tissue carnitine concentrations than healthy lean
rats, while supplementation of L-carnitine to the obese
rats increased tissue carnitine concentrations to levels
found in lean rats [13]. It is unclear however if the above
described change of muscle fiber distribution induced in
obese rats and the restoration of the “normal” muscle
fiber distribution, which is found in lean rats, in obese
rats by supplemental L-carnitine is causally linked with
the carnitine status. In the present study we hypothe-
sized that the fiber type distribution in skeletal muscle is
dependent on the carnitine status. To test this hypothesis
we experimentally manipulated the carnitine status of
young pigs as an animal model through oral administra-
tion of either L-carnitine or sodium pivalate. Administra-
tion of sodium pivalate, the pivalic acid (trimethylacetic
acid) mojety of pivampicillin, is an established model of
secondary carnitine deficiency [17]. In humans, secondary
carnitine deficiency is known to be caused as a side effect
of pharmacologic treatment with pivalate and valproate
and by inborn metabolic disorders, diabetes, renal tubular
loss, haemodialysis and peritoneal dialysis [18]. Pivalic acid
induces carnitine deficiency in both humans and labora-
tory animals by forming excessive tissue levels of pivaloyl-
carnitine esters [19, 20], which are readily released from
tissues and subsequently lost in the urine at a rate that ex-
ceeds endogenous carnitine synthesis. Young pigs were
used as experimental animals, because previous studies of
our group demonstrated that the carnitine concentration
in skeletal muscle of young pigs can be markedly in-
creased within a relatively short feeding period of about
three weeks [21, 22]. In contrast to pigs, studies in healthy
rodents (mice and rats) demonstrated that even high
doses of supplemental L-carnitine cause either no [23, 24]
or only a slight increase of muscle carnitine concentration
[25]. In line with this, fiber type type distribution in
healthy mice was not affected by supplemental carnitine
[24]. Like in mice, studies in human subjects showed that
supplementation of carnitine for several weeks does not
alter the muscle free and/or total carnitine content [26–
28] and the fiber composition of vastus lateralis muscle, a
muscle with a balanced type I and type II fiber distribu-
tion, [28, 29]. Following treatment of pigs for four weeks,
carnitine status was assessed by HPLC-MS/MS and muscle
fiber typing was performed using MHC distribution-based
immunohistochemistry. In addition, the expression of genes
reflecting the metabolic phenotype and genes encoding
critical regulators of muscle fiber transition were determined
in skeletal muscle. In order to exclude the possibility that
sodium pivalate exerts an effect on muscle fiber distribution
independent of its effect on carnitine status we also consid-
ered pigs that received orally sodium pivalate and L-carnitine.
Methods
Animals and diets
The animal experiments were approved by the local Animal
Care and Use Committee (Regierungspräsidium Giessen;
permission no: GI 19/3 No. 30/2013). All experimental
procedures described followed established guidelines for
the care and handling of laboratory animals. Two experi-
ments with 5 weeks old, male crossbred piglets [Pietrain x
(German Landrace x German Edelschwein)] were carried
out. In both experiments, the piglets were kept in pairs in
flat-deck pens under controlled conditions (23 ± 2 °C room
temperature, 50–60% relative humidity, light from
06.00 a.m. to 07.00 p.m.), and all groups received an identi-
cal diet which met the nutrient requirements according to
German Society for Nutrition Physiology [30]. According
to a phase feeding system, the piglets received two diets,
which differed in the protein:energy ratio, throughout the
experiment: one from the start of the experiment until a of
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body weight of 15 kg (phase I), and a second one until the
end of the experiments at day 28 (phase II). The diet in
phase I consisted of (g/kg): wheat, 381.7; barley, 315;
soybean meal (44% CP), 250; soybean oil, 15; mineral and
vitamin premix, 33.5; L-lysin, 2.6; DL-methionine, 1.0 and
L-threonine, 1.2. In phase II the diet consisted of (g/kg):
wheat, 401.9; barley, 302; soybean meal (44% CP), 240; soy-
bean oil, 15; mineral and vitamin premix, 33.4; L-lysin, 1.5;
DL-methionine, 0.5 and L-threonine, 0.7 and a mixture of
organic acids (containing 45% formic acid, 7.7% lactic acid,
5% sodium acetate), 5. The carnitine concentration in the
diets was below 10 mg/kg diet as analyzed by tandem mass
spectrometry according to Hirche et al. [31]. Water was
constantly available ad libitum from nipple drinkers during
both experiments.
In experiment 1, which aimed to determine the effective
pivalate dose, piglets were randomly allocated to five
groups of 4 piglets each. At each day of the 28 days period,
the piglets were given orally either 60 mg NaHCO3/kg
body weight (BW) (group CON), 20 mg L-carnitine and
60 mg NaHCO3/kg BW (group CARN), 30 mg pivalate
(dissolved in NaHCO3)/kg BW (group PIV30), 60 mg
pivalate (dissolved in NaHCO3)/kg BW (group PIV60) or
120 mg pivalate (dissolved in NaHCO3)/kg BW (group
PIV120). The carnitine dose applied is roughly compar-
able to that dose ingested by a piglet consuming daily
770 g of a diet containing 500 mg carnitine/kg. A recent
study of our group with growing pigs showed that a carni-
tine dose of 500 mg/kg diet causes a 2–3-fold increase of
plasma and tissue total carnitine concentrations [21]. The
pivalate doses tested were based on an earlier study, in
which the efficacy of different pivalate doses on tissue car-
nitine concentrations was investigated in rats [32].
In experiment 2, which aimed to study the effect of carni-
tine supplementation and carnitine deficiency on muscle
fiber composition, piglets were randomly allocated to four
groups of 12 piglets each (CON, CARN, PIV, CARN+
PIV). Piglets of groups CON, CARN and PIV were treated
identically as in experiment 1 for the same 28 days period.
Group PIV was identical with group PIV30 of experiment
1, because the pivalate dose 30 mg pivalate/kg BW was
found to be the most effective in inducing carnitine defi-
ciency. Piglets of group CARN+ PIV were given orally
20 mg L-carnitine and 30 mg pivalate (dissolved in
NaHCO3)/kg BW each day throughout the 28 days period.
Sample collection
At day 29, the pigs of both experiments were killed in
the post-prandial period (2 h after their last meal) by
electronarcosis followed by exsanguination. Blood was
collected into heparinized polyethylene tubes (Sarstedt,
Nümbrecht, Germany) and plasma obtained by centrifu-
gation at 1100 x g for 10 min at 4 °C and subsequently
stored at −80 °C. Samples from longissimus dorsi (LD)
and superficial biceps femoris (BF) muscles were imme-
diately collected into 2 ml reaction tubes. After opening
the abdominal cavity, the entire liver was collected and a
small aliquot taken into a 2 ml reaction tube. Subse-
quently, all tissue samples were snap-frozen in liquid ni-
trogen and stored at −80 °C pending analysis.
Carnitine analysis
Tandem mass spectrometry was used for determining the
concentrations of free carnitine and acetyl-carnitine in
plasma, liver and LD and BF muscles according the method
of Hirche et al. [31]. Deuterated L-carnitine-methyl-d3-
hydrochloride and deuterated O-acetyl-d3-carnitine-hydro-
chloride (Sigma-Aldrich, Steinheim, Germany) were used
as internal standards.
Fiber typing of LD and BF muscle
Frozen muscle samples from all pigs were embedded in
Tissue Tek optimal cutting temperature (O.C.T.) com-
pound (Sakura Finetek Germany GmbH, Staufen,
Germany), frozen in liquid nitrogen and stored at −80 °C
until cryosectioning. O.C.T.-embedded muscle samples
were cut into serial 10 μm thick cross-sections with a
microtome (Microm HM 500, Microm International,
Walldorf, Germany) maintained at −20 °C. Fiber typing was
carried out using multicolour immunofluorescence analysis
according to Bloemberg and Quadrilatero [33] with follow-
ing modifications: air-drying for 60 min, fixation in −20 °C
methanol for 10 min prior staining, followed by a washing-
step in 1×PBS and combination of blocking with the appli-
cation of the first antibody cocktail. In brief, air dried and
methanol fixed cross-sections were incubated with a cock-
tail containing primary antibodies against MHC I (BA-F8),
MHC IIb (BF-F3) and all MHC isoforms except MHC IIx
(BF-35) in 1xPBS containing 0.5% Triton X-100 and 10%
goat serum at 4 °C overnight. Primary antibodies were pur-
chased from Developmental Studies Hybridoma Bank (Uni-
versity of Iowa, USA). Following a washing step with 1×
PBS, the cross-sections were incubated with different
fluorescent-conjugated secondary antibodies purchased
from Invitrogen (Darmstadt, Germany) in 1×PBS contain-
ing 0.5% Triton X-100 and 10% goat serum at RT for two
hours. Alexa Fluor 350 IgG2b (blue) was used for BA-F8,
Alexa Fluor 555 IgM (red) for BF-F3 and Alexa Fluor 488
IgG1 (green) for BF-35. Cross-sections were washed again
with 1x PBS, and then mounted in Aqua Polymount
(Polyscience, Niles, Illinois) and covered with coverslips.
The slides were visualized with a DM 5500 B fluorescence
microscope from Leica (Wetzlar, Germany) equipped with
red (Excitation: 485–585 Emission: 535–685), green (Exci-
tation: 440–520, Emission: 497–557) and blue (Excitation:
320–400, Emission: 430–510) filters, a Leica DFC340FX
camera and the Leica LAS AF microscope software. Indi-
vidual images were taken from the slides with each filter
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and a composite image was assembled automatically from
the images taken with the three filters. For fiber typing, per
animal all fibers within two representative fields-of-view at
a 100-fold magnification were counted and typed. Blue
fibers were classified as type I, red fibers as type IIb, green
fibers as type IIa and fibers without staining as type IIx. For
each pig a total of 729 ± 59 (mean ± SD) fibers were
counted/typed in LD muscle and 777 ± 65 (mean ± SD)
fibers in BF muscle.
RNA isolation and qPCR analysis
Total RNA was isolated from 25 mg aliquots of LD and BF
muscles using TRIzol reagent (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s protocol. Con-
centration and purity of the total RNA were estimated from
the optical density at 260 and 280 nm, respectively, using a
NanoQuant Plate and an Infinite 200 M microplate reader
(both from Tecan, Männedorf, Switzerland). The total
RNA concentrations and optical density A260/A280 ratios
of all LD samples were 0.496 ± 0.069 μg/μL and 1.93 ± 0.03
(mean ± SD, n = 48), respectively. The cDNA was synthe-
sized by reverse transcription of 1.2 μg total RNA as de-
scribed recently in detail [34]. The mRNA levels of selected
genes were measured with a Rotor-Gene Q system (Qiagen,
Hilden, Germany) using KAPA™ SYBR® FAST qPCR Mas-
termix (Peqlab, Erlangen, Germany) and gene-specific pri-
mer pairs (Eurofins MWG Operon, Ebersberg, Germany).
Gene-specific primer pairs were designed using Primer3
[35] and BLAST [36]. Characteristics of primers used for
qPCR analysis are shown in Table 1. The amplification of a
single product of the expected size was confirmed using 2%
agarose gel electrophoresis stained with GelRedTM nucleic
acid gel stain (Biotium, Hayward, California, USA). Ct-
values of reference and target genes were obtained using
Rotor-Gene Q software (Qiagen). Ct-values were trans-
formed into relative expression values using the 2-ΔCt equa-
tion for the calculation of normalization factors. The
highest relative value of each gene was set to 1. From these
values, the normalization factor was calculated as the geo-
metric mean of expression data of the three most stable out
of four potential reference genes (ATP5G1, ACTB, RPS9,
SHAS2) according to the method of Vandesompele et al.
[37]. In LD muscle the M-values of the three most stable
reference genes were: 0.498 (ATP5G1), 0.566 (ACTB) and
0.463 (RPS9). In BF muscle the M-values of the three most
stable reference genes were: 0.680 (ATP5G1), 0.747 (ACTB)
and 0.620 (RPS9). Ct-values of target genes were also trans-
formed into relative expression values using the 2-ΔCt equa-
tion and were normalized with the individual normalization
factor resulting in relative gene quantities that were used
for the statistical analysis. The mean normalized 2-ΔCt ratios
of the group CON was set to 1.0 and means and SD of nor-
malized 2-ΔCt ratios of the other groups (CARN, PIV,
CARN+ PIV) were scaled proportionally.
Immunoblotting
Nuclear extracts from LD and BF muscles were prepared
using the Nuclear Extract Kit from Active Motif (Rixensart,
Belgium) according to the manufacturer’s protocol. Protein
concentrations in the nuclear extracts were determined by
the bicinchoninic acid protein assay kit (Interchim, Montlu-
çon, France) with BSA as standard. From the nuclear ex-
tracts, 20 μg was separated by SDS-PAGE (12.5%) and
electrotransferred onto nitrocellulose membranes (Pall
Corporation, Pensacola, FL, USA). Loading of equal amounts
of protein in each lane was verified by Ponceau S (Carl Roth,
Karlsruhe, Germany) staining. After incubating the mem-
branes overnight at 4 °C in blocking solution [Tris-buffered
saline with Tween20 (TBS-T) containing 5% BSA],
membranes were incubated in TBS-T with primary
antibodies against PPARD (rabbit polyclonal anti-PPARD
antibody; 1:500; Abcam, Cambridge, UK), PGC-1 (rabbit
polyclonal anti-PGC-1 antibody; 1:1000; Millipore,
Darmstadt, Germany) and β-actin (mouse monoclonal anti-
β-actin antibody; 1:5000; Abcam) as a reference protein for
normalization overnight at 4 °C. The membranes were
washed, and then incubated in TBS-T with 3% BSA and
Table 1 Characteristics of gene-specific primer pairs used for
qPCR
Gene Forward primer (from 5` to 3`)
Reverse primer (from 5` to 3`)
Product
size (bp)
NCBI
GenBank
Reference genes
ATP5G1 CAGTCACCTTGAGCCGGGCGA
TAGCGCCCCGGTGGTTTGC
94 NM_001025218
ACTB GACATCCGCAAGGACCTCTA
ACATCTGCTGGAAGGTGGAC
205 XM_003124280
RPS9 GTCGCAAGACTTATGTGACC
AGCTTAAAGACCTGGGTCTG
325 XM_003356050
SHAS2 GAAAAGGCTAACCTACCCTG
TGTTGGACAAGACCAGTTGG
218 NM_214053
Target genes
ACADM CATGGCAGCGATGTTTAGGC
GGCACTTGCCCCAGAGTATT
396 NM_214039
CACT ACTGTGACTCAGACGGACCA
ATATAGCCCCCTGACACCCT
235 XM_003483178
COX4 GTGGAACTGTACCGCCTGAA
TTGTCGTAGTCCCACTTGGC
257 XM_003355730
COX6 CTCAGCTCGCATGTGGAAGA
GATGCGAAGATGGGGGTAGG
139 NM_001190221
FATP1 AAGGGCATGGATGATCGACT
ATCACGTCTGTTGCCTGCAT
143 NM_001083931
GLUT4 TCACGTCTCTCGCTGCAGGCT
AAAGCCTGTGGGGACAACACCC
205 NM_001128433
OCTN2 TGCATTTGGCTACATGCTGC
ATGATCACCTCAGCTTCCTG
174 XM_003123912
PKM CAGCAAGAAAGGTGTGAACC
CTCCCTCGTGATTCTCGATT
218 XM_003356683
SDHA CTACGCCCCCGTCGCAAAGG
AGTTTGCCCCCAGGCGGTTG
380 DQ402993
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horseradish peroxidase-conjugated secondary polyclonal anti-
mouse-IgG antibody (rabbit polyclonal; 1:10,000; Abcam) or
anti-rabbit-IgG antibody (goat polyclonal; 1:10,000; Sigma-
Aldrich, Steinheim, Germany) for 2 h at RT. Afterwards,
blots were washed three times with TBS-T and developed
using enhanced chemiluminescence (Amersham ECL Select
Western Blotting Detection Reagent, GE healthcare, Freiburg,
Germany). The signal intensities of specific bands were de-
tected with a Bio-Imaging system (Syngene, Cambridge, UK)
and quantified using Syngene GeneTools software (nonlinear
dynamics; Syngene). For calculation of protein levels, the
band intensity of the proteins of interest was normalized by
that of β-actin.
Statistical analysis
Data are shown as mean values with their standard devi-
ations (SD). The data were subjected to ANOVA using
the Minitab Statistical Software Rel. 13.1 (Minitab, State
College, PA, USA). The data of experiment 1 were sub-
jected to 1-factorial ANOVA and those of experiment 2
to 2-factorial ANOVA with classification factors being
carnitine (CARN), pivalate (PIV) and the interaction of
both factors (CARN x PIV). For statistically significant F
values, individual means of the treatment groups were
compared by Fisher’s multiple range test. Means were
considered significantly different for P < 0.05. The num-
ber of animals used in each group for detecting a statis-
tically significant difference among groups assuming a
hypothesized effect size of 1.40, a type I error of 0.05
(two-sided) and a statistical power of 0.95 was calculated
by G*Power rel. 3.1.2 [38] taking into account the tissue
concentration of total carnitine.
Results
Performance parameters of the pigs in experiments 1 and 2
In both experiments, initial and final body weights, daily
body weight gain, daily feed intake and feed conversion
ratio did not differ between groups (Tables 2 and 3).
Concentrations of free carnitine in plasma, liver and LD
and BF skeletal muscles of pigs in experiment 1
The concentrations of free carnitine in all tissues investi-
gated were 2.1–2.9 fold higher in group CARN than in
group CON (P < 0.05, Fig. 1), but the concentrations of free
carnitine were decreased by 45 to 64% in plasma and tissues
in the PIV30 group compared to the CON group (P < 0.05,
Fig. 1). In groups PIV60 and PIV120 the plasma and tissue
carnitine concentrations were only slightly lower than in the
PIV30 group, but this effect was not significant. Since daily
body weight gains were lower and feed conversion ratios
were higher in the PIV60 and PIV120 groups than in the
PIV30 group, we decided to use 30 mg pivalate/kg BW to
induce carnitine deficiency in experiment 2.
Concentrations of free carnitine and acetyl-carnitine in
plasma, liver and LD and BF skeletal muscles of pigs in
experiment 2
Concentrations of free carnitine and acetyl-carnitine in
plasma, liver and LD and BF skeletal muscles are shown
in Table 4. The concentrations of free and acetyl-carnitine
in all tissues investigated were highest in group CARN.
The concentration of free carnitine in these tissues was
2.0–2.7 fold higher and that of acetyl-carnitine 1.5–3.3
fold higher in group CARN than in group CON (P < 0.05).
Group PIV had the lowest concentrations of free carnitine
and acetyl-carnitine in all these tissues. Concentration of
free carnitine in these tissues was 1.9–2.5-fold lower and
that of acetyl-carnitine 1.8–2.5 fold lower in group PIV
than in group CON (P < 0.05).
The concentrations of free and acetyl-carnitine in
plasma and liver did not statistically differ between
group CARN + PIV and group CON, but the concentra-
tion of free carnitine was 1.2–1.3 fold higher and that of
acetyl-carnitine 1.2–1.8 fold higher in group CARN +
PIV than in group CON. In LD and BF skeletal muscles,
the concentration of free carnitine was 1.3 fold higher in
group CARN + PIV than in group CON (P < 0.5),
whereas the concentration of acetyl-carnitine was similar
between group CARN + PIV and group CON.
Fiber type composition of LD and BF muscles of pigs in
experiment 2
As shown in Fig. 2a (LD muscle) and b (BF muscle), im-
munofluorescence analysis on single muscle cross-sections
enabled us to identify the four major fiber types, type I
(blue), type IIa (green), type IIb (red) and type IIx (un-
stained). For both muscles, fiber typing revealed a predom-
inance of fast type II fibers (85–89%), with type IIb being
the most abundant followed by type IIa and type IIx. The
percentage of slow type I fibers was between 11–13% (LD
muscle) and 16–17% (BF muscle). No differences were ob-
served between the four groups in the percentages of type
I, type IIa, type IIb and type IIx fibers (Fig. 2a and b).
Expression of key regulators of muscle fiber composition
in LD and BF muscles of pigs in experiment 2
To investigate whether the unaltered fiber type composition
is due to the lack of treatment to affect the key regulators
of muscle fiber composition, we determined the mRNA
levels of PPARD, PPARGC1A and PPARGC1B and protein
level of PGC-1α of LD and BF muscles. Figure 3 shows that
the mRNA levels of PPARD, PPARGC1A and PPARGC1B
in LD (a) and BF (c) muscles did not differ between the four
groups of pigs. In addition, the protein level of PGC-1α in
LD (b) and BF (d) muscles were not different between
groups (Fig. 3).
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Expression of genes related to the metabolic phenotype
of LD and BF muscles of pigs in experiment 2
To confirm that the unaltered fiber type composition of skel-
etal muscles between groups is reflected by an unaltered
skeletal muscle metabolic phenotype between groups, the
mRNA levels of genes involved in different energy generating
pathways, such as fatty acid transport and uptake [fatty acid
transporter/solute carrier family 27 member 1 (FATP/
SLC27A1)], β-oxidation [acyl-CoA dehydrogenase, C-4 to C-
12 straight chain (ACADM)], carnitine shuttle [carnitine/
acylcarnitine translocase/solute carrier family 25 member 20
(CACT/SLC25A20)], carnitine uptake [organic cation/carni-
tine transporter/solute carrier family 22 member 5
(OCTN2/SLC22A5)], TCA cycle [succinate dehydrogenase
complex flavoprotein subunit A (SDHA)], oxidative phos-
phorylation [cytochrome c oxidase subunit (COX4I1), cyto-
chrome c oxidase subunit 6A2 (COX6A2)], glucose uptake
[facilitated glucose transporter/solute carrier family 2 mem-
ber 4 (GLUT4/SLC2A4)] and glycolysis [pyruvate kinase,
muscle (PKM)] were determined. In both muscles, the
mRNA levels of all these genes did not statistically differ be-
tween the four groups of pigs (Fig. 4a, LD muscle; b, BF
muscle). However, in BF muscle the mRNA level of OCTN2
was numerically lower in group CARN and group PIV com-
pared to the group CARN+PIV.
Discussion
The main finding of the present study is that the carni-
tine status has no effect on the fiber type composition of
skeletal muscle in healthy growing pigs. This is based on
our observation that the fiber composition of LD and BF
muscles was not different between pigs of the CARN
group and the PIV group, despite a 5–6-fold difference
in plasma and tissue carnitine concentrations. Fiber typ-
ing of both muscles was carried out using immunohisto-
chemistry with monoclonal antibodies against MHC I,
MHC IIb and all MHC isoforms except MHC IIx. In
contrast to the most commonly used method for fiber
typing, myosin adenosine triphosphatase (ATPase) histo-
chemistry, which is based on differences between fiber
types in the sensitivity of their myosin ATPase activity to
pH pre-incubation [39, 40], immunohistochemistry with
MHC-specific antibodies allows to clearly delineate the
pure (I, IIA, IIB, IIX) and even the hybrid fiber types (I/
IIA, IIA/IIX, IIX/IIB) [41]. In the present study, we
could detect the pure fiber types in both muscles. In
addition, we could realize that the fiber type distribution
observed for LD muscle from our pigs is in good agree-
ment with that reported from others using MHC-based
fiber typing [42]; similar to our results these authors
identified approximately 55% of total fibers as type IIB,
12% as type I and 10–20% as type IIA and IIX in porcine
LD muscle. A slight difference between our results and
those of Kim et al. [42] is that we did not identify any
hybrid fibers, which accounted for 7% of total fibers in
LD muscle in the study of Kim et al. [42]. Since we per-
formed fiber typing only in a relatively small area of the
muscle sections and the percentage of hybrid fibers is
Table 2 Performance parameters of pigs in experiment 1
Treatment ANOVA (P-value)
CON
n = 4
CARN
n = 4
PIV30
n = 4
PIV60
n = 4
PIV120
n = 4
Initial body weight 7.71 ± 0.91 7.62 ± 1.02 7.66 ± 0.91 7.35 ± 1.47 7.39 ± 1.59 n.s.
Final body weight (kg) 19.9 ± 1.24 22.3 ± 4.66 19.1 ± 3.51 17.9 ± 5.17 17.9 ± 4.16 n.s.
Daily body weight gain (g) 430 ± 30 520 ± 130 410 ± 90 380 ± 160 380 ± 100 n.s.
Daily feed intake (g) 705 ± 15 545 ± 90 675 ± 115 950 ± 140 740 ± 100 n.s.
Feed conversion ratio (g feed/g gain) 1.71 ± 0.03 1.02 ± 0.40 1.54 ± 0.12 2.36 ± 0.63 1.70 ± 0.55 n.s.
Data are means ± SD. Abbreviations: CON, control group; CARN, carnitine group; PIV30, pivalate 30 mg/kg BW group; PIV60, pivalate 60 mg/kg BW group; PIV120,
pivalate 120 mg/kg BW group; n.s., not significant
Table 3 Performance parameters of pigs in experiment 2
Treatment ANOVA (P-value)
CON
n = 12
CARN
n = 12
PIV
n = 12
CARN + PIV
n = 12
CARN PIV Interaction
Initial body weight 8.05 ± 1.73 7.99 ± 1.22 7.94 ± 0.99 8.00 ± 1.51 n.s. n.s. n.s.
Final body weight (kg) 18.7 ± 3.00 21.4 ± 3.12 20.8 ± 2.71 21.3 ± 4.68 n.s. n.s. n.s.
Daily body weight gain (g) 382 ± 70 472 ± 91 449 ± 76 460 ± 123 n.s. n.s. n.s.
Daily feed intake (g) 739 ± 118 756 ± 184 748 ± 117 841 ± 86 n.s. n.s. n.s.
Feed conversion ratio (g feed/g gain) 1.96 ± 0.26 1.66 ± 0.49 1.67 ± 0.13 1.84 ± 0.18 n.s. n.s. n.s.
Data are means ± SD. Abbreviations: CON, control group; CARN, carnitine group; PIV, pivalate group; CARN + PIV, carnitine + pivalate group; n.s., not significant
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Fig. 1 Concentrations of free carnitine in plasma (a), liver (b), longissimus dorsi (LD) muscle (c) and biceps femoris (BF) muscle (d) of pigs of groups
CON, CARN, PIV30, PIV60 and PIV120 (experiment 1). Bars are means ± SD of n = 4 piglets/group. Bars with different superscript letters differ, P < 0.05
Table 4 Concentrations of free and acetyl-carnitine in plasma and tissues of pigs in experiment 2
Treatment ANOVA (P-value)
CON
n = 12
CARN
n = 12
PIV
n = 12
CARN + PIV
n = 12
CARN PIV Interaction
Plasma, μmol/L
free 5.9 ± 0.9b 15.8 ± 3.8a 2.4 ± 1.0c 7.8 ± 2.8b 0.001 0.001 0.003
acetyl 0.74 ± 0.14b 1.87 ± 0.59a 0.35 ± 0.12c 0.94 ± 0.31b 0.001 0.001 0.009
Liver, nmol/g wet tissue
free 61.2 ± 12.0bc 119.3 ± 23.2a 25.9 ± 8.9c 74.5 ± 30.7b 0.001 0.001 n.s.
acetyl 1.04 ± 0.85bc 3.42 ± 1.83a 0.42 ± 0.55c 1.83 ± 1.47b 0.001 0.004 n.s.
LD muscle, nmol/g wet tissue
free 456 ± 132c 1095 ± 225a 213 ± 62d 609 ± 173b 0.001 0.001 0.011
acetyl 296 ± 57b 440 ± 83a 167 ± 33c 303 ± 78b 0.001 0.001 n.s.
BF muscle, nmol/g wet tissue
free 429 ± 93c 1034 ± 207a 231 ± 64d 547 ± 130b 0.001 0.001 0.001
acetyl 255 ± 44b 459 ± 63a 118 ± 34c 262 ± 65b 0.001 0.001 n.s.
Data are means ± SD. Abbreviations: CON, control group; CARN, carnitine group; PIV, pivalate group; CARN + PIV, carnitine + pivalate group. a, b, c, dValues with
different superscript letters differ, P < 0.05
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generally low, it is possible that no hybrid fibers were
present in our sections by chance. To the best of our
knowledge, no data about fiber distribution of porcine
BF muscle are available from MHC-based fiber typing.
However, our results regarding type I and type IIA fiber
percentages in BF muscle are in agreement with fiber
distribution data reported previously for porcine superfi-
cial BF muscle [43]. In this study a combination of
ATPase and SDH staining, which allows to delineate at
least type I and type IIA fibers, has been used [43]. In
line with the unaffected fiber type composition between
the different groups of pigs, we did not observe any dif-
ferences in the mRNA levels of PPARD, PPARGC1A and
PPARGC1B and the protein levels of PPARδ and PGC-
1α. All of them are regulators of genes involved in type
II to type I fiber transition, mitochondrial biogenesis and
oxidative metabolic pathways through activating a var-
iety of nuclear receptors and additional transcription fac-
tors, like myocyte enhancer factor 2 (MEF2), nuclear
respiratory factor-1 (NRF-1), estrogen-related receptor α
(ERRα) and myofiber regulation factors (MRFs) [9–11].
For instance, activation of the MEF2 family of transcrip-
tion factors stimulates specifically the expression of
MHC genes from oxidative fibers [9, 12], while activa-
tion of NRF-1 and ERRα causes stimulation of oxidative
phosphorylation and mitochondrial biogenesis [44]. Due
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B
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Fig. 2 Fiber type composition of longissimus dorsi (a) and biceps femoris (b) muscle of pigs of the groups CON, CARN, PIV and CARN + PIV
(experiment 2). Representative images were obtained from serial muscle cross-sections incubated with a primary antibody cocktail against MHCI
(BA-F8), MHC IIb (BF-F3) and all MHC isoforms except MHC IIx (BF-35), followed by incubation with appropriate fluorescent-conjugated secondary
antibodies. Images show the four major fiber types, type I (blue), type IIa (green), type IIb (red) and type IIx (unstained). Bars represent fiber type
percentages obtained from fiber counting of immunohistochemically-stained muscle cross-sections at 100-fold magnification and are means ±
SD of n = 12 piglets/group
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to these functions, PGCs and PPARδ are typically higher
expressed in oxidative type I muscle fibers than in glyco-
lytic type II muscle fibers [10] and mRNA expression
PPARs and PGCs correlates with oxidative fiber content
in skeletal muscle [45]. In line with this, transgenic pigs
with overexpression of the PPARGC1A gene in skeletal
muscle have an increased number of type I fibers and
pronounced oxidative phenotype [46]. Also in line with
the unaffected fiber type composition, no differences
were seen in the mRNA levels of genes involved in dif-
ferent energy generating pathways including fatty acid
transport and β-oxidation, TCA cycle, oxidative phos-
phorylation and glycolysis. Thus, our data indicate that
supplemental carnitine has no influence on muscle fiber
transition and the skeletal muscle metabolic phenotype,
which is dependent on the fiber type composition, at
least in growing pigs.
Our observation in growing pigs is in contrast to that
reported recently in obese Zucker rats [13]. In the latter
study L-carnitine supplementation was found to cause
an increased percentage of type I fibers, which are typic-
ally rich in mitochondria and preferentially use fatty
acids for energy production, and a decreased percentage
of glycolytic type II skeletal muscle fibers. In line with
this, the skeletal muscle of the obese rats fed supplemen-
tal L-carnitine exhibited a pronounced oxidative pheno-
type, as evidenced form increased expression levels of
genes involved in fatty acid transport and uptake, β-
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Fig. 3 Relative mRNA and/or protein levels of key regulators of muscle fiber composition, peroxisome proliferator-activated receptor δ (PPARδ)
and PPARγ coactivators (PGCs) in longissimus dorsi (a, b) and biceps femoris (c, d) muscle of pigs of the groups CON, CARN, PIV and CARN + PIV
(experiment 2). A, C: Bars represent means ± SD of n = 12 piglets/group and are relative mRNA levels expressed as fold of group CON which was
to 1.0. C, D: Bars represent means ± SD of n = 6 piglets/group and are relative protein levels expressed as fold of group CON which was to 1.0.
One representative immunoblot for PGC-1 and β-actin is shown. Gene symbols and names: PPARD, peroxisome proliferator activated receptor
delta; PPARGC1A, PPARG coactivator 1 alpha; PPARGC1B, PPARG coactivator 1 beta
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oxidation, carnitine shuttle, carnitine uptake, TCA cycle
and oxidative phosphorylation, compared to obese rats
fed no supplemental L-carnitine [13]. Interestingly, the
rat study which included also a group of lean rats re-
vealed that the obese state is accompanied by a decrease
of type I and an increase of type II fiber percentages in
skeletal muscle and an impairment of carnitine status, −
effects which are reversed to normal by supplementation
of L-carnitine. The L-carnitine-induced type II to type I
fiber transition in obese rats has been explained by the
observed up-regulation of the abovementioned critical
regulators of type II to type I fiber transition, PGC-1α
and PPARδ. Similarly, L-carnitine supplementation was
reported to increase expression of PGC-1α and PPARδ
in rodent models of unloading [5], and genetic and diet-
induced obesity and diabetes [47]. Since in the present
study the carnitine status did not affect the skeletal
muscle phenotype of apparently healthy pigs, it is pos-
sible that supplemental L-carnitine is only effective in
counteracting the change of muscle fiber distribution in-
duced by pathological conditions (obesity, diabetes,
unloading). Nevertheless, we cannot exclude the possi-
bility that the lack of effect of carnitine status in pigs is a
species-specific phenomenon which warrants further
investigations.
With regard to the situation in human, it has to be
mentioned that the dose of supplemental L-carnitine
used in this study (20 mg/kg body weight) is roughly
comparable to that of a 80 kg person receiving 2 g sup-
plemental L-carnitine, which is a typical oral L-carnitine
dose used in clinical trials with healthy and ill subjects
(see reviews by [48, 49]). In addition, the dose is of
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Fig. 4 Relative mRNA levels of genes related to the metabolic phenotype in longissimus dorsi (a) and biceps femoris (b) muscles of pigs of the
groups CON, CARN, PIV and CARN + PIV (experiment 2). Bars represent means ± SD of n = 12 piglets/group and are expressed as fold of group CON
which was to 1.0. Gene symbols and names: ACADM, acyl-CoA dehydrogenase, C-4 to C-12 straight chain; CACT/SLC25A20, carnitine/acylcarnitine
translocase/solute carrier family 25 member 20; COX4I1, cytochrome c oxidase subunit 4I1; COX6A2, cytochrome c oxidase subunit 6A2; FATP/SLC27A1,
fatty acid transporter/solute carrier family 27 member 1; GLUT4/SLC2A4, facilitated glucose transporter/solute carrier family 2 member 4; OCTN2/
SLC22A5, organic cation/carnitine transporter/solute carrier family 22 member 5; PKM, pyruvate kinase, muscle; SDHA, succinate dehydrogenase
complex flavoprotein subunit A
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relevance for athletes regularly consuming carnitine sup-
plements, which are advocated to improve exercise per-
formance through enhancing muscle fatty acid oxidation
and decreasing reliance on endogenous carbohydrate
stores, despite the fact that most of the available clinical
studies failed to demonstrate such an effect [26, 48].
One important reason explaining the failure of L-
carnitine supplementation to alter muscle fuel metabol-
ism and to improve exercise performance in most clin-
ical studies is probably that carnitine ingestion does not
increase muscle free and/or total carnitine content, at
least in humans [26–29]. Regarding published effects of
supplemental L-carnitine on muscle fiber composition in
humans, it has been reported in two independent studies
that the fiber composition of vastus lateralis muscle, a
muscle with a balanced type I and type II fiber distribu-
tion, is not changed by L-carnitine supplementation (ei-
ther 4 g/day for 6 weeks [50] or 2 × 2 g/day for three
month [29]). Thus, the observations in both humans and
pigs suggest that supplemental L-carnitine has no effect on
muscle fiber composition, despite the fact that the fiber
type composition of muscles considered in our pig study
differs from that of vastus lateralis muscle. Our assumption
is based on the observation that L-carnitine supplementa-
tion failed to alter muscle fiber composition in pigs, even
though muscle carnitine concentration was strongly in-
creased by the supplemental L-carnitine. The latter obser-
vation is in line with previous studies in young pigs [21,
22]. In the study of Fischer et al. [21] it was shown that the
concentration free and total carnitine in muscle (LD muscle
and semimembranosus muscle) as well as in plasma, heart,
liver and kidney linearly increased with increasing dietary
L-carnitine supply (0, 25, 50, 100, 200, 500 and 1000 mg/kg
diet) during a 20 days feeding period. At the highest dose of
1000 mg L-carnitine/kg diet, muscle total carnitine concen-
tration of pigs was 5-fold higher than in non-supplemented
pigs [21]. The reason for the lack of increase of muscle car-
nitine concentration of humans in response to supplemen-
tal L-carnitine is unclear. It has been proposed that species-
differences in the bioavailability of supplemental L-carnitine
may account for this. While in humans the bioavailability
of high oral L-carnitine doses of 1 to 6 g was found to be
less than 20% [51–53], in pigs a very high intestinal carni-
tine absorption rate of >90% has been reported even at a
high supplementation level of 1000 mg L-carnitine/kg diet
[21]. Similar as in humans, studies in rats demonstrated
that high doses of supplemental L-carnitine cause either no
[23] or a markedly lower increase of muscle carnitine con-
centration compared to pigs; a study from our own group
with healthy rats demonstrated that feeding a high dose of
supplemental L-carnitine (5000 mg/kg diet) for three weeks
increased muscle free and total carnitine concentration only
by about 50% [25]. The weaker response of the rat com-
pared to the pig may indeed be explained by a lower
intestinal absorption rate of carnitine which was deter-
mined by the indicator method to be 38% [25]. However,
considering that intravenous L-carnitine infusion in
humans also failed to impact on muscle carnitine concen-
tration suggests that species differences in the intestinal
carnitine absorption rate alone cannot explain the different
response of pig, human and rat muscle to supplemental L-
carnitine. Based on this, it is much more likely that muscle
carnitine transport is the limiting factor to muscle carnitine
accumulation. Since carnitine is transported into skeletal
muscle against a considerable concentration gradient of
greater than 100-fold via a saturable, sodium-dependent,
high affinity, active transport process [54], which is cata-
lyzed by the novel organic cation transporter 2 (OCTN2)
[55], it appears possible that species differences exist in the
expression level of OCTN2 in skeletal muscle. Despite the
renal carnitine reabsorption, which is dependent on
OCTN2 transport activity in the kidney, is known to be
generally high across different mammals, it cannot be ex-
cluded that differences in the OCTN2-mediated carnitine
reabsorption rate between humans or rats and pigs may be
causative for higher renal carnitine losses in humans or rats
compared to pigs. This however has to be clarified in future
studies. In addition, future studies have to clarify whether
long-term supplementation of carnitine in pigs is able to
cause fiber switching.
Conclusion
The present study clearly shows that significant changes in
the systemic carnitine status and the muscle carnitine
concentration induced by either supplementing L-carnitine
or administering pivalate have no impact on the contractile
and metabolic phenotype of skeletal muscles containing
predominantly type II muscle fibers in pigs. Given that
recent studies reported that supplemental L-carnitine has
no effect on muscle fiber composition in humans, it can be
concluded that pigs and humans behave similar with regard
to this phenotypic trait, despite both species differ largely
with regard to their ability to accumulate dietary carnitine
in muscle.
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